Attached files
| file | filename |
|---|---|
| 10-K/A - 10K-A2 2010 - JUNIPER PHARMACEUTICALS INC | form10ka.htm |
| EX-23.1 - EXHIBIT 23.1 - JUNIPER PHARMACEUTICALS INC | exhibit231.htm |
| EX-23.2 - EXHIBIT 23.2 - JUNIPER PHARMACEUTICALS INC | exhibit232.htm |
| EX-32.2 - EXHIBIT 32.2 - JUNIPER PHARMACEUTICALS INC | exhibit322.htm |
| EX-31.1 - EXHIBIT 31(I).1 - JUNIPER PHARMACEUTICALS INC | exhibit31i1.htm |
| EX-31.2 - EXHIBIT 31(I).2 - JUNIPER PHARMACEUTICALS INC | exhibit31i2.htm |
EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Columbia Laboratories, Inc. (the “Company”) on Form 10-K/A, Amendment No. 2 for the period ended December 31, 2009 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Frank C. Condella Jr., Interim Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
|
(1)
|
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
|
|
(2)
|
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
|
|
/s/Frank C. Condella, Jr.
|
|
|
Frank C. Condella, Jr.
|
|
|
Interim Chief Executive Officer
December 28, 2010
|